A Aforeworn
Forewarned is forearmed.
Home › Niches › Pharmaceutical Manufacturing (FDA/DEA) › Change
Low urgency

Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant from Schedule IV into Schedule V

Detected August 10, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

FDA/DEA reschedules suvorexant, lemborexant, and daridorexant from Schedule IV to Schedule V, easing regulatory controls.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 10, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Manufacturers, distributors, and dispensers of suvorexant, lemborexant, and daridorexant. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective date not specified in the excerpt; check the full Federal Register notice for the effective date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

These three drugs are moved from Schedule IV to Schedule V, reducing regulatory requirements (e.g., lower recordkeeping, less stringent security, and lower quota burdens).

Who it affects

Manufacturers, distributors, and dispensers of suvorexant, lemborexant, and daridorexant.

What you must do

Review and update internal controlled-substance procedures to reflect Schedule V status; adjust DEA registrations and quotas as needed.

Deadline

Effective date not specified in the excerpt; check the full Federal Register notice for the effective date.

Source: https://www.federalregister.gov/public-inspection/2026-16375/schedules-of-controlled-substances-rescheduling-of-suvorexant-lemborexant-and-daridorexant-from

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)